Tirzepatide
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Eli Lilly · Phase 2 · Not yet recruiting · Enrollment 224
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo Comparator: Placebo | n/r | n/r | n/r | n/r |
| Placebo + Tirzepatide 5 mg | n/r | n/r | n/r | n/r |
| Placebo + Tirzepatide 10 mg | n/r | n/r | n/r | n/r |
| NA-931 60mg to NA-931 150 mg + no Tirzepatide | n/r | n/r | n/r | n/r |
| NA-931 60 mg + Tirzepatide 5 mg | n/r | n/r | n/r | n/r |
| NA-931 120 mg + Tirzepatide 5 mg | n/r | n/r | n/r | n/r |
| NA-931 150 mg + no Tirzepatide | n/r | n/r | n/r | n/r |
| NA-931 150 mg + Tirzepatide 2.5 mg | n/r | n/r | n/r | n/r |
| NA-931 150 mg + Tirzepatide 5 mg | n/r | n/r | n/r | n/r |
Not shown
- Placebo Comparator: Placebo: endpoint not reported
- Placebo + Tirzepatide 5 mg: endpoint not reported
- Placebo + Tirzepatide 10 mg: endpoint not reported
- NA-931 60mg to NA-931 150 mg + no Tirzepatide: endpoint not reported
- NA-931 60 mg + Tirzepatide 5 mg: endpoint not reported
- NA-931 120 mg + Tirzepatide 5 mg: endpoint not reported
- NA-931 150 mg + no Tirzepatide: endpoint not reported
- NA-931 150 mg + Tirzepatide 2.5 mg: endpoint not reported
- NA-931 150 mg + Tirzepatide 5 mg: endpoint not reported